Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

NYBA recognizes Acorda Therapeutics President with The Cures Start Here Business Leader of the Year Award

Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President and Chief Executive Officer, is the recipient of the New York Biotechnology Association "The Cures Start Here" Business Leader of the Year Award. The award is presented for outstanding service to the patient community and to NYBA.

8 Jun 2010

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

Providers of home medical equipment and services across Pennsylvania are proposing a fiscally responsible alternative to the mislabeled "competitive" bidding scheme currently under way in Medicare that will actually discourage competition, reduce access to care for many of Pennsylvania's more than two million Medicare beneficiaries, and put hundreds of Pennsylvania's homecare providers out of business.

8 Jun 2010

Optical coherence tomography shows promise for multiple sclerosis diagnosis

A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study.

8 Jun 2010

CXCR4 protein may aid restore damage from MS and other neurodegenerative diseases: Researchers

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

8 Jun 2010

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

7 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

7 Jun 2010

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva Pharmaceutical Industries Ltd. today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.

5 Jun 2010

Study confirms Azilect as a selective MAO-B inhibitor

Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.

4 Jun 2010

Multiple sclerosis risk sharing scheme: A costly failure

The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today. They argue that the biggest losers are the other NHS patients who would otherwise have benefited from the money spent on the scheme, estimated to be around -50m per year since it was set up in 2002.

4 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

UCI study provides blueprint for enhanced treatment of inflammatory diseases

By discovering how adult neural stem cells navigate to injury sites in the central nervous system, UC Irvine researchers have helped solve a puzzle in the creation of stem cell-based treatments: How do these cells know where to go? Tom Lane and Kevin Carbajal of the Sue and Bill Gross Stem Cell Research Center found the answer with the body's immune system.

2 Jun 2010

Motion Therapeutics to launch BalanceWear Stabilizing Garments for MS

For those who suffer from balance disorders and loss of mobility, promising results from a new stabilizing device may help to reestablish mobility, confidence and independence. This week, Motion Therapeutics premieres its BalanceWear™ Stabilizing Garments at the 24th Annual Meeting for the Consortium of Multiple Sclerosis Centers in San Antonio.

2 Jun 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

NYBA recognizes Acorda Therapeutics President with The Cures Start Here Business Leader of the Year Award

Medicare bidding program will lead to 'suicide bidding', says Pennsylvania Association of Medical Suppliers

Optical coherence tomography shows promise for multiple sclerosis diagnosis

CXCR4 protein may aid restore damage from MS and other neurodegenerative diseases: Researchers

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Study confirms Azilect as a selective MAO-B inhibitor

Multiple sclerosis risk sharing scheme: A costly failure

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

UCI study provides blueprint for enhanced treatment of inflammatory diseases

Motion Therapeutics to launch BalanceWear Stabilizing Garments for MS

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in